Candriam S.C.A. Merus N.V. Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MRUS
# of Institutions
200Shares Held
61.9MCall Options Held
243KPut Options Held
300K-
Rtw Investments, LP New York, NY4.17MShares$178 Million3.32% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.41MShares$146 Million3.17% of portfolio
-
Commodore Capital LP New York, NY3.35MShares$143 Million14.22% of portfolio
-
Wellington Management Group LLP Boston, MA2.89MShares$124 Million0.03% of portfolio
-
Samlyn Capital, LLC New York, NY2.61MShares$112 Million2.1% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $1.96B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...